Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Treatable cardiac disease in hospitalised COPD exacerbations

Paul Leong, Martin I. MacDonald, Paul T. King, Christian R. Osadnik, Brian S. Ko, Shane A. Landry, Kais Hamza, Ahilan Kugenasan, John M. Troupis, Philip G. Bardin
ERJ Open Research 2021 7: 00756-2020; DOI: 10.1183/23120541.00756-2020
Paul Leong
1Monash Lung and Sleep, Monash Health, Clayton, Victoria, Australia
2School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
7These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin I. MacDonald
1Monash Lung and Sleep, Monash Health, Clayton, Victoria, Australia
2School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
7These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul T. King
1Monash Lung and Sleep, Monash Health, Clayton, Victoria, Australia
2School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paul.leong@monash.edu
Christian R. Osadnik
1Monash Lung and Sleep, Monash Health, Clayton, Victoria, Australia
3School of Primary and Allied Health Care, Monash University, Frankston, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian R. Osadnik
Brian S. Ko
2School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
4Monash Heart, Monash Health, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane A. Landry
1Monash Lung and Sleep, Monash Health, Clayton, Victoria, Australia
2School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kais Hamza
5School of Mathematical Sciences, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahilan Kugenasan
6Monash Imaging, Monash Health, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Troupis
2School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
6Monash Imaging, Monash Health, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip G. Bardin
1Monash Lung and Sleep, Monash Health, Clayton, Victoria, Australia
2School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction Acute exacerbations of COPD (AECOPD) are accompanied by escalations in cardiac risk superimposed upon elevated baseline risk. Appropriate treatment for coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) could improve outcomes. However, securing these diagnoses during AECOPD is difficult, so their true prevalence remains unknown, as does the magnitude of this treatment opportunity. We aimed to determine the prevalence of severe CAD and severe HFrEF during hospitalised AECOPD using dynamic computed tomography (CT).

Methods A cross-sectional study of 148 patients with hospitalised AECOPD was conducted. Dynamic CT was used to identify severe CAD (Agatston score ≥400) and HFrEF (left ventricular ejection fraction ≤40% and/or right ventricular ejection fraction ≤35%).

Results Severe CAD was detected in 51 of 148 patients (35%), left ventricular systolic dysfunction was identified in 12 cases (8%) and right ventricular systolic dysfunction was present in 18 (12%). Clinical history and examination did not identify severe CAD in approximately one-third of cases and missed HFrEF in two-thirds of cases. Elevated troponin and brain natriuretic peptide did not differentiate subjects with severe CAD from nonsevere CAD, nor distinguish HFrEF from normal ejection fraction. Undertreatment was common. Of those with severe CAD, only 39% were prescribed an antiplatelet agent, and 53% received a statin. Of individuals with HFrEF, 50% or less received angiotensin blockers, beta blockers or antimineralocorticoids.

Conclusion Dynamic CT detects clinically covert CAD and HFrEF during AECOPD, identifying opportunities to improve outcomes via well-established cardiac treatments.

Abstract

Severe, treatable cardiac disease is present during hospitalised #AECOPD exacerbations, and is often clinically unsuspected. This cardiac disease can be detected with dynamic CT. Appropriate treatment could change outcomes. https://bit.ly/2Is45wO

Footnotes

  • This article has supplementary material available from openres.ersjournals.com.

  • This study is registered at www.anzctr.org.au with identifier number ACTRN12617001562369. Institutional ethics approval was obtained for data sharing in aggregated and deidentified formats only.

  • Author contributions: Conception, design: P. Leong, M.I. MacDonald, P. King, C.R. Osadnik, B.S. Ko, A. Kugenasan, J.M. Troupis and P.G. Bardin; acquisition and analysis: P. Leong, M.I. MacDonald, B.S. Ko, S.A. Landry, K. Hamza, A. Kugenasan and J.M. Troupis; interpretation: P. Leong, M.I. MacDonald, P. King, C.R. Osadnik, B.S. Ko, J.M. Troupis and P.G. Bardin; first draft: P. Leong. All authors participated in revising the work, agreed to submit this version for publication, and agree to be accountable for all aspects of the work.

  • Conflict of interest: P. Leong has nothing to disclose.

  • Conflict of interest: M.I. MacDonald has nothing to disclose.

  • Conflict of interest: P. King has nothing to disclose.

  • Conflict of interest: C.R. Osadnik has nothing to disclose.

  • Conflict of interest: B.S. Ko reports personal fees from Canon Medical during the conduct of the study.

  • Conflict of interest: S.A. Landry has nothing to disclose.

  • Conflict of interest: K. Hamza has nothing to disclose.

  • Conflict of interest: A. Kugenasan has nothing to disclose.

  • Conflict of interest: J.M. Troupis has nothing to disclose.

  • Conflict of interest: P.G. Bardin has nothing to disclose.

  • Support statement: P. Leong is supported by the Australian National Health and Medical Research Council Postgraduate Scholarship, the Royal Australasian College of Physicians Dixon Award, and the Monash Lung and Sleep Institute. C.R. Osadnik was the recipient of a Lung Foundation Australia COPD Research Fellowship and is the recipient of a Rebecca L. Cooper Medical Research Foundation Project Grant, unrelated to the present work. Views expressed are those of the authors and may not represent those of the funding bodies. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received October 16, 2020.
  • Accepted November 5, 2020.
  • Copyright ©ERS 2021
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

View Full Text
PreviousNext
Back to top
Vol 7 Issue 1 Table of Contents
ERJ Open Research: 7 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatable cardiac disease in hospitalised COPD exacerbations
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Treatable cardiac disease in hospitalised COPD exacerbations
Paul Leong, Martin I. MacDonald, Paul T. King, Christian R. Osadnik, Brian S. Ko, Shane A. Landry, Kais Hamza, Ahilan Kugenasan, John M. Troupis, Philip G. Bardin
ERJ Open Research Jan 2021, 7 (1) 00756-2020; DOI: 10.1183/23120541.00756-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treatable cardiac disease in hospitalised COPD exacerbations
Paul Leong, Martin I. MacDonald, Paul T. King, Christian R. Osadnik, Brian S. Ko, Shane A. Landry, Kais Hamza, Ahilan Kugenasan, John M. Troupis, Philip G. Bardin
ERJ Open Research Jan 2021, 7 (1) 00756-2020; DOI: 10.1183/23120541.00756-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original articles

  • Endobronchial autologous BM-MSCs in IPF patients
  • Effect of β-blockers on the risk of COPD exacerbations
  • Recurrence of symptoms after childhood LRTI
Show more Original articles

COPD

  • SNPs in SUMF1 are associated with lung function and COPD
  • Predictors of COPD in women who never smoked
  • EFL in a cohort of highly symptomatic COPD patients
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2022 by the European Respiratory Society